Web-based mindfulness intervention in heart disease: A randomized controlled trial by Younge, J.O. (John) et al.
RESEARCH ARTICLE
Web-Based Mindfulness Intervention in Heart
Disease: A Randomized Controlled Trial
John O. Younge1,2, Machteld F. Wery2, Rinske A. Gotink2,3,5, Elisabeth M. W. J. Utens4,
Michelle Michels1, Dimitris Rizopoulos6, Elisabeth F. C. van Rossum7, M. G.
Myriam Hunink2,5,8☯, Jolien W. Roos-Hesselink1☯*
1 Department of Cardiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The
Netherlands, 2 Department of Epidemiology, Erasmus MC, University Medical Center Rotterdam,
Rotterdam, The Netherlands, 3 Department of Psychiatry (Section Medical Psychology and Psychotherapy),
Erasmus MC Rotterdam, University Medical Center, Rotterdam, The Netherlands, 4 Department of
Adolescent Psychiatry/Psychology, Erasmus MC Rotterdam, University Medical Center, Rotterdam, The
Netherlands, 5 Department of Radiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam,
The Netherlands, 6 Department of Biostatistics, Erasmus MC, University Medical Center Rotterdam,
Rotterdam, The Netherlands, 7 Department of Internal Medicine, Erasmus MC, University Medical Center
Rotterdam, Rotterdam, The Netherlands, 8 Department of Health Policy and Management, Harvard T.H.
Chan School of Public Health, Boston, MA, United States of America
☯ These authors contributed equally to this work.
* j.roos@erasmusmc.nl
Abstract
Background
Evidence is accumulating that mindfulness training has favorable effects on psychological
outcomes, but studies on physiological outcomes are limited. Patients with heart disease
have a high incidence of physiological and psychological problems and may benefit from
mindfulness training. Our aim was to determine the beneficial physiological and psychologi-
cal effects of online mindfulness training in patients with heart disease.
Methods
The study was a pragmatic randomized controlled single-blind trial. Between June 2012 and
April 2014 we randomized 324 patients (mean age 43.2 years, 53.7%male) with heart dis-
ease in a 2:1 ratio (n = 215 versus n = 109) to a 12-week online mindfulness training in addi-
tion to usual care (UC) compared to UC alone. The primary outcome was exercise capacity
measured with the 6 minute walk test (6MWT). Secondary outcomes were other physiological
parameters (heart rate, blood pressure, respiratory rate, and NT-proBNP), subjective health
status (SF-36), perceived stress (PSS), psychological well-being (HADS), social support
(PSSS12) and a composite endpoint (all-cause mortality, heart failure, symptomatic arrhyth-
mia, cardiac surgery, and percutaneous cardiac intervention). Linear mixed models were
used to evaluate differences between groups on the repeated outcomemeasures.
Results
Compared to UC, mindfulness showed a borderline significant improved 6MWT (effect size,
meters: 13.2, 95%CI: -0.02; 26.4, p = 0.050). There was also a significant lower heart rate in
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favor of the mindfulness group (effect size, beats per minute: -2.8, 95%CI: -5.4;-0.2, p =
0.033). No significant differences were seen on other outcomes.
Conclusions
Mindfulness training showed positive effects on the physiological parameters exercise
capacity and heart rate and it might therefore be a useful adjunct to current clinical therapy
in patients with heart disease.
Trial Registration
Dutch Trial Register 3453
Introduction
In recent decades, cardiovascular disease (CVD) has become the foremost cause of health bur-
den worldwide.[1] Especially the group of adults with congenital heart disease has increased
over the last decades. While cardiovascular disease cause significant stress,[2] chronic stressors
such as anxiety and depression are themselves independent risk factors for cardiovascular mor-
bidity and mortality.[3, 4] Chronic stress can negatively affect not only quality of life, but also
physiological parameters such as respiration rate, heart rate, blood pressure, inflammatory
markers and brain activity.[5]
As heart rate is associated with long-term survival, patients are recommended to try reduc-
ing heart rate in the management and prevention of CVD.[6] Often medication, such as beta-
blockers, is prescribed for this goal. Stress reduction in itself may also have a beneficial effect
on heart rate and physical fitness. While the best approach to stress management is unclear,
increased attention is now being paid to lifestyle interventions such as mindfulness therapy.[7,
8] Mindfulness is described as the capacity to live with open and non-judgmental awareness
towards all experiences within the present moment.[9, 10] Several core features, such as medi-
tation, yoga, and cognitive assignments, can increase the ability to accept negative experience
or emotions.[11] Mindfulness therapy has been found to positively affect psychological out-
comes in patients with chronic pain, obesity, hypertension, depression, anxiety and cardiovas-
cular disease.[12–16]
We hypothesized that, besides these psychological effects, mindfulness therapy may influ-
ence heart rate, breathing patterns and blood pressure through a favorable effect on the auto-
nomic nervous system and therefore may positively affect exercise capacity and thus long-term
outcome[17]. In a randomized controlled trial (RCT), we therefore investigated the effective-
ness of online mindfulness training on exercise capacity in patients with heart disease.
Methods
Study design
The current study is a single blinded, pragmatic RCT performed at the outpatient cardiology
clinic of the Erasmus MC, Rotterdam, The Netherlands. Ethical approval was obtained from
the Medical Ethics Committee (METC) of the Erasmus Medical Center and the study complied
with the Declaration of Helsinki (S1 and S2 Texts). The study was registered at the Dutch trial
register, 3453, http://www.trialregister.nl. Patients received written information about the
study at home, 2–4 weeks prior to their scheduled visit to the cardiologist at the outpatient
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clinic. Full disclosure was given about the nature of the intervention. The current study reports
the results of 3 month follow-up, which ended in July 2014, whereas the 12-month follow-up is
still ongoing.
Participants
Adult patients, between 18 and 65 years of age, with diagnosed heart disease (ischemic, valvu-
lar, congenital heart disease, or cardiomyopathy) were eligible for inclusion between June 2012
and April 2014. Patients were excluded based on the following criteria: (1) planned operation
or percutaneous intervention within the upcoming year; (2) inability or unwillingness to give
informed consent; (3) inability to understand Dutch, inability to read or write Dutch; (4) no
internet access, email, or cell phone; (5) patients who did not fill out the baseline questionnaires
or did not show up for the scheduled baseline tests. All participants provided written informed
consent.
Intervention
The active intervention was mindfulness training which consisted of a 12-week structured stan-
dardized online program. The training was offered in addition to usual care (UC) as provided
by the treating cardiologist. All patients received a book about mindfulness by a renowned
author to support the 12-week training[18]. The training was designed to be self-directed and
to be easily accessible and engaging to a wide audience by keeping practice sessions and lessons
short. The program teaches different meditations, self-reflection, and yoga. Furthermore, it
includes practical assignments and suggestions for mindfulness in day-to-day life. The use of
breath as a reminder for present moment awareness is emphasized in all meditations. The pro-
gram was divided into four components (S1 Table). During the course participants also
received biweekly reminders by e-mail and standardized text messages. Adherence to the inter-
vention was monitored by whether the questions of the online program were completed. For
privacy reasons, the content of the answers remained undisclosed. Both the program and the
book were provided free of charge to participating patients.
Control
The control group received UC by their treating cardiologist. Treatment and frequency differs
between patients, but general components are regular outpatient visits, lifestyle advice regard-
ing nutrition, smoking, exercise, stress reduction, medication and other procedures if indicated.
We chose for a pragmatic study design without a placebo online training in order to measure
effectiveness rather than efficacy. This choice is justified by the likelihood of a partial placebo
effect that is part-and-parcel of the training as it would be implemented in future practice.
Randomization
After a patient’s eligibility was established by one of the study investigators, written informed
consent was obtained and baseline measurements were performed. Subsequently, patients were
randomized according to a 2:1 ratio via dedicated computer software (ALEA1) with a block
size of 12 to receive the online Mindfulness training or UC.[19] The investigator entered the
patients into the computer software, but did not receive the result of the allocation. The result
of the randomization procedure was sent to an independent employee (medical secretary) of
the outpatient clinic, who was not involved in establishing eligibility, outcome assessment, or
data analyses. Subsequently, this employee contacted the participant with the result and pro-
vided instructions on how to access the web-based training.
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Blinding
Due to the nature of the intervention, blinding of patients was not feasible. The intervention
started as soon as patients logged on to the mindfulness training website. The outcome asses-
sors (investigators) were unaware of patients’ treatment allocation. Therefore, the design of
this study can be considered as a single-blinded randomized controlled trial in which the inves-
tigators remained blinded throughout the duration of the study. Additionally, patients were
instructed not to say anything about their treatment allocation, neither to study investigators
nor to their cardiologist.
Outcome measures
Outcomes were measured in all patients pre- (T0) and post-intervention (12 weeks, T1).
We were interested in evaluating the physical effects of mindfulness and thus chose as pri-
mary outcome measure the 6MWT, which is an overall measure of exercise tolerance, has
reproducible results, and has shown to be an independent predictor of long term outcome.[20–
22] The 6MWT was performed in a 20-meter-long corridor at the outpatient clinic.[23] The
corridor had well-indicated ‘start’ and ‘finish’ marks with colored pawns.
Secondary outcome measures
Physical parameters. Weight, blood pressure, respiratory rate and heart rate. BMI was cal-
culated by weight in kilograms divided by height in meters squared. Blood pressure was mea-
sured using an automated non-invasive monitor (Mindray Datascope Duo) after the
participant had rested for 5 minutes in the sitting position. This monitor also reports the heart
rate. Respiratory rate was measured in rest within a set amount of 30 seconds.
Blood sampling laboratory tests. N-terminal pro-brain natriuretic peptide (NT-proBNP,
Elecsys system, Roche Diagnostics, Basel, Switzerland: normal values 14pmol/L) and creati-
nin were measured from peripheral venous blood samples.
Subjective health status. The Short-Form Health survey 36 (SF-36) was used to evaluate
subjective health status. For each of the 8 subdomains a transformed score is generated, ranging
from 0 to 100,[24] with a higher score indicating better health.[25] The subdomains were used
to construct the mental component summary (MCS) measure, which consists of the subdo-
mains vitality, social functioning, role-emotional functioning and mental health, and the physi-
cal component summary (PCS) measure, which consists of the subdomains physical
functioning, role physical functioning, bodily pain and general health.[26]
A Visual Analogue Scale (VAS) was used to assess subjective perceived QoL (“Indicate on
the line above where you would situate yourself in terms of your overall quality of life”, ranging
from 0 to 100, with a higher score indicating better QoL.[27]
Psychological well-being. To assess symptoms of anxiety and depression, the Hospital
Anxiety and Depression scale was used. The questionnaire contains 14 items on depression
and anxiety with a higher score on the 3 point Likert scale indicating a greater level of emo-
tional distress.[28]
Stress. The Dutch version of the Perceived Stress Scale (PSS) was used to evaluate per-
ceived stress. The scale consists of fourteen 5-point Likert scales, with a higher score indicating
a higher level of stress (0 = never, 4 = very often). A total perceived stress score is made by sum-
ming all individual items.[29]
Social support. To evaluate perceived social support, the Dutch version of the Perceived
Social Support Scale 12 Blumenthal (PSSS12) was used. The PSSS12 has 12 items with a
7-point Likert scale addressing the degree of perceived social support with a higher score
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indicating a greater feeling of support (1 = very strongly disagree, 7 = very strongly agree).[30]
For the purpose of this study we used the total score.
Adverse events. Adverse events were defined as all-cause mortality, heart failure, symp-
tomatic arrhythmia, cardiac surgery, and percutaneous cardiac intervention. Arrhythmias were
defined as symptomatic if antiarrhythmic medication was prescribed, cardioversion or ablation
had been applied, or a pacemaker or intracardiac defibrillator (ICD) was implanted. Heart fail-
ure was defined as an event when either medication or hospitalization was necessary.
Other study parameters
In order to document baseline risk levels, traditional cardiovascular risk factors and demo-
graphics were determined: age, sex, length, weight, smoking, type of heart disease, and employ-
ment status. Additionally participation in other mindfulness-based exercises and the use of
other complementary care was monitored with a questionnaire (type, frequency, and
intensity).
Quality control and audit
The digitalization of the paper case record forms (CRFs) in the database was independently
performed by 2 persons (JY and MW). After digitalization, an error rate of<0.5% was
observed between JY and MW. An independent audit was performed and the study was found
to comply with Good Clinical Practice and Scientific Integrity standards.
Sample size justification
To demonstrate an improvement of 5% in the intervention group vs 1% in the control group
on the 6MWT, this study required 99 patients in the control group and 198 in the active inter-
vention group (SD10%, alpha = 0.05, power = 0.90, ratio experimental to controls = 2). Even if
only 50% of patients in the experimental group adhered to the training, this would give us a
power of 0.80 in the as-treated analysis. To account for non-adherence and loss to follow-up
our aim was to randomize at least 300 patients. This number of patients is sufficient to demon-
strate a smaller difference (5% in the intervention group vs 2% in the control group) in a
repeated measurements analysis with a power of 75% (2 follow-up measurements, correlation
between follow up measurements = 0.70, correlation between baseline & follow-up = 0.50).
Statistical analysis
Descriptive analyses were performed to describe the baseline characteristics of demographic
and clinical variables stratified by treatment group. Changes in outcomes at 12 weeks com-
pared with baseline (intragroup effect) and differences between treatment groups (difference
in delta’s, intergroup effect) on physiological and psychological outcomes were calculated. To
simultaneously account for the correlation between the multiple measurements of each patient
and dropout, a repeated measurements analysis was performed using a multivariate linear
regression mixed model to determine intergroup effects. In the mean structure of the mixed
model we included the time effect, the intervention effect and their interaction, while a fully
unstructured variance-covariance matrix was assumed for the error terms. Due to randomiza-
tion only p-values for the interaction effect are reported.
An intention-to-treat (ITT) analysis was performed to address whether offering a mindful-
ness training was effective compared to UC. An as-treated (AT) analysis was performed to
address whether the mindfulness training was beneficial if actually performed. In the AT analy-
sis, patients were considered adherent if they completed 50% or more of the exercises. Patients
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allocated to the UC group who sought mindfulness training on their own were excluded from
the AT analysis.
For both ITT and AT, Cohen’s D was calculated to enable comparison of effect sizes. This
calculation was performed based on the results of the mixed model.
A p-value less than 0.05 was considered to be indicative of statistical significance. All data
were analyzed with IBM SPSS Statistics version 21.0 (IBM Corp., Somers, NY).
Results
Patient recruitment and characteristics
A flowchart of the patients’ recruitment is shown in Fig 1. Patients’ baseline characteristics
(Table 1) demonstrated no significant differences between the intervention and control group
which confirmed a successful randomization, also on important characteristics such as: age
(p = 0.98) and, gender (p = 0.28). In total, 5 patients did not complete any assignment of the
mindfulness training whereas 115 patients completed at least 50% of the assignments (as-
treated analysis) with a mean (SD) 53% (34).
Safety/side effects
No major side effects were reported during the follow-up period. In 7 patients (5 mindfulness
(2.3%), 2 control (1.8%)) at baseline and 13 patients (8 mindfulness (4.8%), 5 control (5.5%))
at follow-up, fatigue, dizziness, shortness of breath, or pain due to pre-existing conditions were
described while performing the 6MWT.
Outcome analysis
At 12 weeks, the mindfulness group showed a notable improvement on their mean 6MWT,
which was borderline significantly different compared with UC (p = 0.050) (Table 2). The
intergroup comparison showed that heart rate was significantly lower in the mindfulness
group (p = 0.033) (Table 2). Mean systolic and mean diastolic blood pressure decreased in the
mindfulness and UC group, but no significant differences were found in the intergroup com-
parison (Table 2). The results of the physiological outcomes are summarized in Fig 2.
Analyses showed no significant differences between the groups on the PCS and MCS of the
SF-36 (Table 2). At 12 weeks, anxiety levels were lower than baseline scores in both the mind-
fulness and the UC group, but no significant differences were found in the intergroup compari-
son (Table 2).
Depressive symptoms decreased at 12 weeks, but did not significantly differ between the
groups. Neither perceived stress scores nor perceived social support were statistically signifi-
cant different in the intergroup comparison (Table 2). No significant differences were found on
adverse events. The results of the psychological outcomes are summarized in Fig 3.
The results of AT-analyses were comparable with the ITT analyses (Table 3).
Cohen’s D
In order to compare different outcome measures, Cohen’s D effect sizes were calculated. In the
intention-to-treat analyses (Figs 4 and 5), heart rate and depression showed, small, but signifi-
cant improvement (D = 0.20, 95%CI 0.04 to 0.36 and d = 0.17, 95%CI 0.01 to 0.33 respectively).
In the As-Treated analysis, exercise capacity, heart rate, systolic blood pressure and stress
improved significantly, with small effect sizes ranging from D = 0.19 to D = 0.21 (Figs 6 and 7).
Mindfulness in Heart Disease
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Discussion
To our knowledge, this is the first randomized trial to evaluate the effectiveness of mindfulness
training in patients with heart disease. By taking physiological parameters as its main outcome
Fig 1. Flowchart of mindfulness training and control group.
doi:10.1371/journal.pone.0143843.g001
Mindfulness in Heart Disease
PLOS ONE | DOI:10.1371/journal.pone.0143843 December 7, 2015 7 / 19
Table 1. Baseline characteristics of study participants.
Mindfulness
Group N = 215
Control Group
N = 109
Demographics
Age (years), mean (SD) 43.2 (14.1) 43.2 (13.7)
Female (%) 44.2 50.5
Physiological parameters
Heart rate (beats/min),
mean (SD)
68 (12) 69 (11)
Systolic blood pressure
(mm Hg), mean (SD)
128 (16) 125 (15)
Diastolic blood pressure
(mm Hg), mean (SD)
78 (11) 80 (10)
Resting respiratory rate
(breaths/min), median
(IQR)
15 (2) 15 (3)
Body mass index (kg/m2),
mean (SD)
25.9 (4.6) 25.7 (4.7)
Obesity* (%) 16.7 15.6
Psychological parameters
PCS, mean (SD) 46.6 (9.6) 45.3 (10.3)
MCS, mean (SD) 50.2 (10.6) 50.8 (9.6)
HADS Anxiety, mean (SD) 8.2 (3.6) 9.0 (3.4)
HADS Depression, mean
(SD)
3.8 (2.9) 3.8 (2.9)
VAS, mean (SD) 75.0 (13.2) 72.7 (13.2)
PSS, mean (SD) 22.4 (7.8) 22.0 (7.5)
PSSS12, mean (SD) 69.5 (11.6) 71.5 (12.3)
Exercise tolerance
6 minute walk test
distance (meters),
mean (SD)
537.5 (77.0) 539.3 (67.3)
Laboratory works
NT-proBNP, median
(IQR), pmol/L
16.7 (28.5) 18.3 (33.9)
Creatinine, median (IQR),
μmol/L
79.0 (21.0) 77.0 (21.0)
Cardiac history, type of heart disease, (%)
Congenital heart disease 41.9 42.2
Cardiomyopathy 39.5 29.4
Valvular heart disease 18.6 28.4
Other comorbidity, (%)
Diabetes Mellitus** 3.2 3.7
Number of interventions in
life***, mean (SD)
1.4 (1.4) 1.4 (1.2)
Time since ﬁrst
intervention (years),
mean (SD)
19.1 (14.0) 15.9 (11.7)
ICD, (%) 5.9 4.3
PM, (%) 9.3 5.2
Current medication (%) 70.2 72.5
Beta-blocker 43.2 36.7
(Continued)
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parameter, it is also an innovative study. On the primary endpoint–exercise capacity–we found
a borderline significant but clinically small effect in favor of mindfulness. Heart rate also
decreased significantly more with mindfulness training. Remarkably, no significant improve-
ments were found on subjective outcome measures, although anxiety and depressive symptoms
did decrease.
Limited exercise capacity is an important predictor for outcome for cardiac disease, and sev-
eral studies have reported an association with survival.[17, 31–33] Since a decrease in physical
performance is also an important predictor of adverse outcomes in patients with congenital
heart disease, improving physical performance may be an important target of treatment. In
recent years, cardiac rehabilitation programs, many of them conducted in patients with post-
myocardial infarction, have had good results on total and cardiovascular mortality.[34, 35]
Our results indicate that mindfulness training could be part of future treatment modalities
intended to improve physical performance in heart disease patients. It remains to be shown
whether this will also affect long-term outcome. Several epidemiological studies in patients
with hypertension, acute coronary syndromes,[36] stable coronary heart disease[37] and heart
Table 1. (Continued)
Mindfulness
Group N = 215
Control Group
N = 109
Statin 18.6 13.8
Aspirin 16.3 14.7
Ace-inhibitor 23.3 22.0
Angiotensin II antagonist 8.8 11.9
Calcium channel blocker 9.8 6.4
Nitroglycerin 2.3 0.0
Cardiac glycoside 2.3 2.8
Diuretic 16.8 19.3
Anticoagulant 24.6 33.9
Antidepressant 5.1 2.8
Tranquilizer 1.9 1.8
Other 43.3 57.8
Intoxication, (%)
Current smoking 14.4 18.3
Current alcohol use 62.1 55.0
Current drugs use 3.3 2.8
Work status
Employed, (%) 68.7 67.9
Prior use of
complementary
therapies****, (%)
14.4 12.8
* Obesity was deﬁned when the BMI was 30 kg/m2.
** Diabetes was deﬁned when a patient reported use of anti-diabetes medication.
*** Include both surgical and percutaneous interventions.
**** Contains yoga, meditation, mindfulness, tai chi, Qigong and acupuncture.
SD, standard deviation; PCS, physical component summary measure; MCS, mental component summary
measure; VAS, visual analogue scale; HADS, hospital anxiety and depression scale; PSS, perceived
stress score; PSSS12, perceived social support; NT-proBNP, N-terminal pro-Brain Natriuretic Peptide; IQR,
interquartile range; ICD, implantable cardioverter-deﬁbrillator; PM, pacemaker.
doi:10.1371/journal.pone.0143843.t001
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failure[38] have shown that resting heart rate is a risk factor for cardiovascular and all-cause
mortality. These epidemiological results suggest that the beneficial effect of mindfulness on
heart rate demonstrated in our study is clinically meaningful.
To date, very few studies have evaluated mindfulness training in patients with cardiac dis-
ease. A pilot study that offered a brief mindfulness-based stress-reduction program to patients
with, or at risk of, coronary artery disease[16] showed significant but moderate reductions on
two psychological outcomes, depression (Cohen’s d = 0.54) and perceived stress (d = 0.68).
Unlike in our study, the participants were not randomized and the intervention was fairly
short (4-weeks). Two reports of the same study population showed that mindfulness-based
Table 2. Changes in outcomes at 12 weeks compared with baseline (intragroup effect) and differences between treatment groups (difference in
delta’s, intergroup effect) on physiological and psychological outcomes. Intention-to-treat analyses.
Physiological outcomes Treatment group Delta 12-weeks vs baseline
(intragroup)a (mean, SD)
Effect Estimate
(intergroup) b
95% CI p-value
6MWT, meters Mindfulness 10.42 (49.0) 13.2 -0.02; 26.4 0.050
UC -4.0 (55.6)
Heart rate, beats/min Mindfulness -2 (10.9) -2.8 -5.4; -0.2 0.033
UC 0.5 (9.0)
SBP, mmHg Mindfulness -4.2 (15.4) -2.2 -6.1; 1.7 0.268
UC -1.9 (15.5)
DBP, mmHg Mindfulness -1.9 (8.9) 1.6 -0.8; 4.0 0.186
UC -3.4 (10.1)
Respiratory rate, breaths/minute* Mindfulness -0.5 (3.6) -0.02 -0.04; 0.01 0.189
UC -0.1 (4.0)
NT-proBNP, pmol/L* Mindfulness 0.3 (9.7) -0.04 -0.1; 0.04 0.333
UC 0.0 (11.10)
Psychological outcomes
SF-36 PCS Mindfulness 0.5 (6.3) -0.4 -2.0; 1.3 0.668
UC 0.7 (6.7)
SF-36 MCS Mindfulness 0.2 (7.4) 0.74 -1.4; 2.8 0.489
UC 1.2 (8.8)
VAS Mindfulness 0.4 (10.4) -0.4 -3.0; 2.1 0.745
UC 0.7 (9.3)
HADS Anxiety Mindfulness -0.5 (3.2) 0.6 -0.2; 1.4 0.145
UC -0.9 (3.0)
HADS Depression Mindfulness -0.5 (2.9) -0.4 -1.1; 0.2 0.203
UC 0.0 (2.3)
PSS Mindfulness -2.4 (6.3) -1.0 -2.7; 0.6 0.226
UC -0.9 (6.8)
PSSS12 Mindfulness 0.6 (7.4) 0.4 -1.6: 2.4 0.685
UC 0.1 (8.0)
SD, standard deviation; SE, standard error; 6MWT, six-minute walk test; UC, usual care; SBP, systolic blood pressure; DBP, diastolic blood pressure; NT-
proBNP, N-terminal pro-brain natriuretic peptide; SF-36, Short Form Health survey; PCS, physical component summary measure; MCS, mental
component summary measure; VAS, visual analogue scale; HADS, hospital anxiety and depression scale; PSS, perceived stress score; PSSS12,
perceived social support.
* Effect estimates are calculated from log-transformed scores.
a Delta value (follow-up measurement minus baseline, intragroup effect) was calculated for those who attended the 12-week follow-up.
b Linear mixed model analyses for repeated measurements for differences between treatment groups (intergroup effect) on the dependent variables (time
X intervention effect).
doi:10.1371/journal.pone.0143843.t002
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stress-reduction mainly improved anxiety, emotional control and coping, rather than resting-
stress hormones or physical functioning.[39, 40] Recently, a brief group-MBSR intervention in
patients undergoing a percutaneous coronary intervention showed favorable effects on quality
of life.[41] Additionally, anxiety, depression, and stress appeared to be influenced positively
but only in the younger age group (<60 years).[41] Lastly, an individual MBSR training in
patients with coronary heart disease showed significant reductions in anxiety, depression, per-
ceived stress and the physiological parameters BP and BMI.[42] However, this study had lim-
ited power and was only performed in males. In contrast to previous reports, in our study
psychological outcomes did not significantly improve by mindfulness training. Whereas in pre-
vious studies patients were often selected on the basis of reduced psychological well-being, in
our study they were not. In fact, baseline psychological scores were similar to scores in the gen-
eral population[43–47] implying that improvement was hardly possible (a ceiling effect). Also,
our training was online without any personal contact, which probably resulted in smaller
effects. There is increased interest in the effect of acceptance and commitment therapy, which
has similarities with mindfulness training, focusing on the relationship between persons’ own
thoughts and feelings that could potentially have a positive effect on several modifiable CVD
risk factors.[48]
Similar to the ceiling effect for psychological outcomes, we observed a floor effect for blood
pressure, as our patients had regular blood pressure monitoring and (extra) medication was
given when necessary. Previous studies, some of which showed potential benefits on blood pres-
sure, investigated populations whose blood pressures at baseline were higher than average.[7, 49]
Fig 2. Forest plot of physiological outcomes. All values on the left of the Y-axis indicate a difference in favour of the mindfulness group. 6MWT, six-minute
walk test; IC, confidence interval, NT-proBNP, N-terminal pro-brain natriuretic peptide; * Log-transformed scores.
doi:10.1371/journal.pone.0143843.g002
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Accumulating evidence suggests that mind and body do indeed show an interaction and
that physiological changes are underlain by several neuro-humoral mechanisms. For example,
in an extensive study of a framework in mind-body medicine, Benson and colleagues focused
on the relaxation response as a core component in autonomic function and physical changes.
[50, 51] It has been shown that, through emotions and thoughts, the autonomic nervous sys-
tem is key in the brain-heart connection.[52] By working through the autonomic nervous sys-
tem, mind-body practices can also benefit endothelial, neuroendocrine and immune function.
[53–55] However, the mechanism between the mind and body is not merely unidirectional:
several levels of the neuro-axis have been found to contribute to the “top-down and bottom-up
mechanisms” in mind-body practices.[56]
To date, web-based mindfulness training studies have been limited to small studies on stress
reduction. A study by Gluck et al.[57] reported a trend towards lower levels of stress. Two
other studies on online mindfulness training showed not only that it was feasible to conduct
online mindfulness training, but also that it was effective in reducing stress.[58, 59] It is impor-
tant to emphasize that their study populations consisted of mainly females recruited from the
healthy general population, and in one, no randomization was performed.
Limitations of the current study must be addressed. Our own study used neither a placebo
nor a waiting list for the control group. We considered the placebo effect of the online training
to be inherent to the active intervention: we evaluated the training and the control as they
Fig 3. Forest plot of psychological outcomes. All values on the left of the Y-axis indicate a difference in favour of the mindfulness group. CI, confidence
interval; SF-36, Short Form Health survey; VAS, visual analogue scale; HADS, hospital anxiety and depression scale; PSS, perceived stress score;
PSSS12, perceived social support.
doi:10.1371/journal.pone.0143843.g003
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would be implemented in real-world practice and measured effectiveness rather than efficacy.
We acknowledge that by doing so our study is pragmatic rather than explanatory. Our inclu-
sion of the placebo effect as part of the mindfulness intervention compared with UC without
placebo in the control group is further justified by the fact that no competing therapy exists.
Every placebo online training similar to the intervention we could think of would likely have
an unwanted beneficial effect in the control group.
Another limitation is that only 80.6% (n = 261) of the patients returned for follow-up. Rea-
sons for trial discontinuation were not reported due to recommendations from the local ethics
committee. A possible explanation for the follow-up rate is the fact that the intervention was
not offered in a group-based setting. The impact of online training may be lower than that of
Table 3. Changes in outcomes at 12 weeks compared with baseline (intragroup effect) and differences between treatment groups (intergroup
effect) on physiological and psychological outcomes, as-treated analyses.
Physiological outcomes Treatment group Delta 12-weeks* (mean, SD) Estimate† 95% CI p
6MWT, meters Mindfulness 9.36 (35.9) 10.6 -1.7; 23.0 0.091
UC -1.92 (51.7)
Heart rate, beats/min Mindfulness -3.07 (11.7) -3.4 -6.3; 0.4 0.027
UC 0.47 (9.2)
SBP, mmHg Mindfulness -5.17 (14.5) -3.8 -8.0; 0.3 0.072
UC -1.50 (15.5)
DBP, mmHg Mindfulness -2.34 (8.9) 0.8 -1.8; 3.5 0.524
UC -3.39 (10.1)
Respiratory rate, breaths/minute Mindfulness -0.67 (3.5) -0.7 -1.8; 0.3 0.170
UC -0.11 (4.1)
NT-proBNP, pmol/L‡ Mindfulness 1.03 (28.7) -0.04 -0.2; 0.09 0.540
UC 4.73 (21.7)
Psychological outcomes
SF-36 PCS Mindfulness 0.7 (6.4) 0.13 -1.7; 2.0 0.893
UC 0.4 (6.8)
SF-36 MCS Mindfulness -0.05 (7.5) 1.2 -1.1; 3.5 0.302
UC 1.5 (8.9)
VAS Mindfulness 0.4 (10.4) -0.2 -3.0; 2.6 0.878
UC 0.7 (9.3)
HADS Anxiety Mindfulness -0.5 (3.2) 0.5 -0.4; 1.4 0.267
UC -0.9 (3.0)
HADS Depression Mindfulness -0.5 (2.9) -0.4 -1.2; 0.3 0.267
UC 0.0 (2.3)
PSS Mindfulness -2.4 (6.3) -1.1 -3.0; 0.8 0.244
UC -0.9 (6.8)
PSSS12 Mindfulness 0.6 (7.4) 0.5 -1.7; 2.6 0.670
UC 0.1 (8.0)
SD, standard deviation; SE, standard error; 6MWT, six-minute walk test; UC, usual care; SBP, systolic blood pressure; DBP, diastolic blood pressure;
IQR, interquartile range; SE, standard error, NT.
proBNP, N-terminal pro-brain natriuretic peptide; SF-36, Short Form Health survey; VAS, visual analogue scale; HADS, hospital anxiety and depression
scale; PSS, perceived stress score; PSSS12, perceived social support.
* Delta value (follow-up measurement minus baseline, intragroup effect) was calculated for those who attended the 12-week follow-up.
† Linear mixed model analyses for repeated measurements for differences between treatment groups on the dependent variables (time X intervention
effect).
‡ Effect estimates are calculated from log-transformed scores.
doi:10.1371/journal.pone.0143843.t003
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personal or group training. While this would mean that the results of mindfulness therapy may
therefore be even stronger in other settings, the easy accessibility of online training may have
allowed better generalizability of the results, as patients could do the training in their own
Fig 4. Forest plot showing the Intention-to-Treat Cohen’s D results of the effectiveness of the mindfulness intervention compared with usual care
on the physiological outcomes. The width of the line indicates the 95%CI. All values lower than 0 indicate a significant difference in favour of the
mindfulness group.
doi:10.1371/journal.pone.0143843.g004
Fig 5. Forest plot showing the Intention-to-Treat Cohen’s D results of the effectiveness of the mindfulness intervention compared with usual care
on the psychological outcomes. The width of the line indicates the 95%CI. All values lower than 0 indicate a significant difference in favour of the
mindfulness group.
doi:10.1371/journal.pone.0143843.g005
Fig 6. Forest plot showing the As-Treated Cohen’s D results of the effectiveness of the mindfulness intervention compared with usual care on the
physiological outcomes. The width of the line indicates the 95%CI. All values lower than 0 indicate a significant difference in favour of the mindfulness
group.
doi:10.1371/journal.pone.0143843.g006
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environment and fit it into a busy schedule. Although we monitored participants’ training
activity, detailed adherence was difficult to assess and control for. Furthermore, ethical consid-
erations prevented us from blinding patients to the nature of the intervention during the
informed consent procedure and patients’ expectation of the interventions was not addressed.
The control group was therefore aware that the online mindfulness training was available and
that they were not receiving it. This could have led to selective follow-up but we found no sig-
nificant difference between the groups at follow-up with regard to demographic and clinical
variables. A placebo lifestyle intervention in the control group could underestimate the effec-
tiveness of the active intervention compared to what can be expected in real-world practice.
Thus, rather than comparing to a unrealistic placebo intervention, we considered the placebo
effect as part-and-parcel of the procedure. In addition, we did not assess maintenance of blind-
ing, but the inability to blind patients could have potentially led to unblinding of the investiga-
tors (outcome assessors), even though extensive precautions were made to limit this bias.
Conclusions
Online mindfulness training is feasible in patients with heart disease and shows a small positive
effect on exercise capacity and heart rate. The current study found no significant effect on psy-
chological outcomes.
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